Avizakimab, formerly known as BOS161721, represents a novel clinical approach to treating autoimmune disorders. This monoclonal medication selectively targets IL18, a crucial signaling molecule implicated in https://kiarasvtv240990.activoblog.com/52520166/avizakimab-a-detailed-exploration-into-bos161721-s-capability